# Kumar Srinivasan

> Kumar Srinivasan is the President and CEO of Wugen, a St. Louis clinical-stage biotech building off-the-shelf memory NK and CAR-T cell therapies for cancer. A chemist turned dealmaker, he spent 25+ years in pharma and biotech business development, most notably engineering the partnering strategy at Turning Point Therapeutics that culminated in its $4.1 billion acquisition by Bristol Myers Squibb. Since taking Wugen's helm in March 2023, he has steered its lead programs WU-CART-007 and WU-NK-101 into pivotal and early clinical trials.

- **Role:** President & CEO at Wugen
- **Organizations:** Wugen, Turning Point Therapeutics, AstraZeneca, Wyeth, Vivoryon Therapeutics (Probiodrug AG), TorreyPines Therapeutics
- **Nationality:** American
- **Education:** Dual B.S./M.S. in Chemistry, University of Madras, Ph.D. in Organic Chemistry, Case Western Reserve University, Postdoctoral research, California Institute of Technology (Caltech), MBA, concentration in Finance and Strategy, University of Chicago Booth School of Business
- **Known for:** Led the partnering strategy at Turning Point Therapeutics that resulted in its $4.1 billion acquisition by Bristol Myers Squibb, Drove WU-CART-007 to FDA Breakthrough Therapy designation and a pivotal trial in T-cell malignancies, Advanced WU-NK-101, the first candidate from Wugen's memory NK cell platform, into the clinic for AML

## Career timeline

- **—** — Senior business development roles at TorreyPines Therapeutics, Vivoryon (Probiodrug AG) and Wyeth
- **—** — VP and Global Head of Business Development, BioPharmaceuticals unit, AstraZeneca (9+ years)
- **2020** — Led pandemic-related licensing for AstraZeneca's COVID-19 vaccine and monoclonal antibody programs
- **—** — EVP and Chief Business Officer, Turning Point Therapeutics; led partnering strategy ending in $4.1B acquisition by Bristol Myers Squibb
- **2023** — Appointed President and CEO of Wugen, effective March 13, 2023
- **2024** — Wugen initiates pivotal trial of WU-CART-007 in relapsed/refractory T-ALL/T-LBL
- **2025** — Wugen raises Series C; total funding reaches $323M

## Achievements

- Led the partnering strategy at Turning Point Therapeutics that resulted in its $4.1 billion acquisition by Bristol Myers Squibb
- Drove WU-CART-007 to FDA Breakthrough Therapy designation and a pivotal trial in T-cell malignancies
- Advanced WU-NK-101, the first candidate from Wugen's memory NK cell platform, into the clinic for AML
- Built and executed in- and out-licensing deals across multiple therapeutic areas during 9+ years at AstraZeneca

## Latest updates

- **2025-08** — Wugen closed a Series C round; total funding reported at $323M.
- **2024-11** — Wugen initiated a pivotal trial for WU-CART-007 in relapsed/refractory T-ALL and T-LBL.

## Links

- Website: https://wugen.com
- LinkedIn: http://www.linkedin.com/in/kusrinivasan

---

Profile page: https://yespress.io/kumar-srinivasan
Published by YesPress — https://yespress.io
Last updated: 2026-06-11